Improved Histone Deacetylase Inhibitors as Therapeutics for the Neurodegenerative Disease Friedreich’s Ataxia: A New Synthetic Route by Joel M. Gottesfeld, James R. Rusche, Elisabetta Soragni, Vincent Jacques, Chunping Xu

Get full text

Mechanism of action of 2-aminobenzamide HDAC inhibitors in reversing gene silencing in Friedreich’s ataxia by Elisabetta eSoragni, C. James Chou, James R. Rusche, Joel M. Gottesfeld

Get full text

Development of frataxin gene expression measures for the evaluation of experimental treatments in Friedreich's ataxia. by Heather L Plasterer, Eric C Deutsch, Matthew Belmonte, Elizabeth Egan, David R Lynch, James R Rusche

Get full text

The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington's Disease Mice. by Haiqun Jia, Ying Wang, Charles D Morris, Vincent Jacques, Joel M Gottesfeld, James R Rusche, Elizabeth A Thomas

Get full text

Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model. by Myriam Rai, Elisabetta Soragni, C James Chou, Glenn Barnes, Steve Jones, James R Rusche, Joel M Gottesfeld, Massimo Pandolfo

Get full text

Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model by Chiranjeevi Sandi, Ricardo Mouro Pinto, Sahar Al-Mahdawi, Vahid Ezzatizadeh, Glenn Barnes, Steve Jones, James R. Rusche, Joel M. Gottesfeld, Mark A. Pook

Get full text